B lymphomas escape Id-specific killer T cells: does this preclude Id vaccination? Recent in silico findings by Veelken and coworkers suggest that B lymphoma–derived Ig V-region Id peptides bind poorly to the patient's own HLA class I molecules, indicating that only lymphoma cells which escape immunosurveillance by Id-specific CD8⁺ T cells progress into clinical cancers.²  Nevertheless, they now show that Id vaccination of patients can elicit Id-specific responses including CD8⁺ responses.¹  These results indicate that B-lymphoma patients are not totally devoid of lymphoma-reactive Id-specific CD8⁺ T cells and that these can be stimulated by vaccination with patient Fab fragments produced in bacteria. (Professional illustration by Paulette Dennis.)